首页> 外文期刊>IBRO Reports >Targeting the difficult-to-drug CD71 and MYCN with gambogic acid and vorinostat an a class of neuroblastomas
【24h】

Targeting the difficult-to-drug CD71 and MYCN with gambogic acid and vorinostat an a class of neuroblastomas

机译:用藤黄酸和伏立诺他靶向一类难以治疗的CD71和MYCN,是一类神经母细胞瘤

获取原文
           

摘要

Diffuse brain gliomas are most common type of primary brain tumors and associated with poor prognosis. In this study, we aimed to reveal impact of IDH1 mutation status on long term patient prognosis. The human Cannabinoid receptor 1 (CB1) receptor which is acti- vated by endocannabinoids is expressed in the peripheral nervous system and central nervous system. And this endocannabinoid sys- tem also related to many health conditions and diseases, such as anxiety, motor control, drug behavioral addictions. Therefore, CB1 is a promising therapeutic target for a variety of disorders. Dis- tinct efficacy profiles showed different therapeutic effects on CB1 dependent on three classes of ligands: agonists, antagonists, and inverse agonists. To discriminate the distinct efficacy profiles of the ligands, we carried out molecular dynamics (MD) simulations to identify the dynamic behaviors of inactive and active conforma- tions of CB1 structures with the ligands. In additions, the molecular mechanics Poisson-Boltzmann surface area (MM-PBSA) method was applied to analyze the binding free energy decompositions of the CB1-ligand complexes. With these two methods, we found the possibility that the three classes of ligands can be discriminated. Our findings shed light on the understanding of different efficacy profiles of ligands by analyzing the structural behaviors of intact.
机译:弥漫性脑神经胶质瘤是最常见的原发性脑肿瘤,与预后不良有关。在这项研究中,我们旨在揭示IDH1突变状态对长期患者预后的影响。被内源性大麻素激活的人大麻素受体1(CB1)受体在周围神经系统和中枢神经系统中表达。而且这种大麻素系统还与许多健康状况和疾病有关,例如焦虑,运动控制,药物行为成瘾。因此,CB1是多种疾病的有希望的治疗靶标。不同的功效谱显示对CB1的不同治疗效果取决于三类配体:激动剂,拮抗剂和反向激动剂。为了区分配体的不同功效,我们进行了分子动力学(MD)模拟,以鉴定具有配体的CB1结构的非活性和活性构象的动力学行为。此外,分子力学泊松玻尔兹曼表面积(MM-PBSA)方法用于分析CB1配体配合物的结合自由能分解。使用这两种方法,我们发现可以区分三类配体的可能性。我们的发现通过分析完整的结构行为,为理解配体的不同功效谱提供了启示。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号